Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-...

por Zhou, Zheng-Yi, Tang, Wenxi, Villa, Kathleen F
Publicado 2018

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US

por Strand, Vibeke, Husni, Elaine, Griffith, Jenny, Zhou, Zheng-Yi, Signorovitch, James, Ganguli, Arijit
Publicado 2016

Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis

por Zhou, Zhou, Fan, Yanni, Thomason, Darren, Tang, Wenxi, Liu, Xinyue, Zhou, Zheng-Yi, Macaulay, Dendy, Fischer, Aryeh
Publicado 2019

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

por Richter, Joshua, Lin, Peggy L., Garcia‐Horton, Viviana, Guyot, Patricia, Singh, Erin, Zhou, Zheng‐Yi, Sievert, Mark, Taiji, Riley
Publicado 2023

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

por Loong, Herbert H., Wong, Carlos K.H., Chan, Catherine P.K., Chang, Andrea, Zhou, Zheng-Yi, Tang, Wenxi, Gibbs, Meaghan
Publicado 2022

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A

por Zhou, Zheng-Yi, Raimundo, Karina, Patel, Anisha M., Han, Simeng, Ji, Yusi, Fang, Honghao, Zhong, Jia, Betts, Keith A., Mahajerin, Arash
Publicado 2020

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA

por Bensimon, Arielle G., Zhou, Zheng-Yi, Jenkins, Madeline, Song, Yan, Gao, Wei, Signorovitch, James, Krepler, Clemens, Scherrer, Emilie, Wang, Jingshu, Aguiar-Ibáñez, Raquel
Publicado 2020

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Chan, Catherine P. K., Chang, Andrea, Zhou, Zheng-Yi, Xie, Jipan, Gibbs, Meaghan
Publicado 2020

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the Uni...

por Huang, Min, A. Fasching, Peter, Haiderali, Amin, Xue, Weiguang, Yang, Chelsey, Pan, Wilbur, Zhou, Zheng-Yi, Hu, Peter, Chaudhuri, Mitashri, Le Bailly De Tilleghem, Celine, Cappoen, Nicolas, O’Shaughnessy, Joyce
Publicado 2023

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

por Goldschmidt, Jerome, Hart, Lowell, Scott, Jeffrey, Boykin, Kristen, Bailey, Ray, Heritage, Trevor, Lopez-Gonzalez, Lorena, Zhou, Zheng-Yi, Edwards, Marie Louise, Monnette, Alisha, Ogbonnaya, Augustina, Deyoung, Kathryn, Venkatasetty, Divea, Shi, Ping, Aton, Lindsay, Huang, Huan, Conkling, Paul R., Gordan, Lucio
Publicado 2023